CHRM2

Muscarinic acetylcholine receptor M2 · P08172 · CHRM2 on Sugi Atlas →

557,489 patent compounds predicted against CHRM2, 350,059 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Dimethindene (SCHEMBL18759)	1.00	19/20
Trospium (SCHEMBL25785)	1.00	11/20
Oxapium (SCHEMBL24857)	0.41	10/20
Tiotropium (SCHEMBL4589)	1.00	8/20
Carbinoxamine (SCHEMBL5070)	1.00	8/20
Tiotropium (SCHEMBL8625)	1.00	8/20
Drofenine (SCHEMBL25124)	1.00	8/20
Hexocyclium (SCHEMBL25730)	0.81	8/20
Xenytropium (SCHEMBL24707)	0.69	8/20
Fentonium (SCHEMBL24583)	0.67	8/20
Fentonium (SCHEMBL24584)	0.67	8/20
Cyclandelate (SCHEMBL5123)	0.54	8/20
Fenpiverinium (SCHEMBL23654)	0.53	8/20
Carbamoylcholine (SCHEMBL2792)	1.00	7/20
Ipratropium (SCHEMBL3124)	1.00	7/20
Ipratropium (SCHEMBL3125)	1.00	7/20
Acetylcholine (SCHEMBL3216)	1.00	7/20
Butylscopolamine (SCHEMBL25291)	0.98	7/20
Butylscopolamine (SCHEMBL25292)	0.98	7/20
Ipratropium (SCHEMBL3852)	0.98	7/20

Clinical trials — most relevant to CHRM2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Preventive Effects of Penehyclidine Hydrochloride Inhalation on Postoperative Pulmonary Complications	PHASE4	COMPLETED
Anti-inflammatory Effects of Tiotropium in Patients with Stable COPD	PHASE4	COMPLETED
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia	PHASE4	COMPLETED
Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization or Death from Any Cause	PHASE4	COMPLETED
Galantamine for Cognition in People With Schizophrenia	PHASE4	COMPLETED
Metoclopramide as Treatment of Clozapine-induced Hypersalivation	PHASE3	COMPLETED
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease	PHASE1/PHASE2	RECRUITING
A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma	PHASE2	COMPLETED
Nicotinic Receptors and Schizophrenia	PHASE1/PHASE2	WITHDRAWN
Bryophyllum Versus Placebo for Overactive Bladder	PHASE2	COMPLETED
Pilot Study of Pyridostigmine Upon Immune Activation in HIV-1 Patients Who Have an Inadequate Immune Response	PHASE2	COMPLETED
Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition	PHASE2	RECRUITING
A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS	PHASE2	RECRUITING
A Positron Emission Tomography Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants	PHASE1	NOT_YET_RECRUITING
M1 Schizophrenia PET Study	PHASE1	COMPLETED
Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants	PHASE1	COMPLETED
Cholinergic Mechanisms of Attention in Aging	EARLY_PHASE1	COMPLETED
Toward a Computationally-Informed, Personalized Treatment for Hallucinations	EARLY_PHASE1	RECRUITING
Preemptive Oral Gabapentin and Tramadol on Postoperative Pain After Knee Arthroscopy	nan	COMPLETED
Methacholine, Long-acting M-cholinolytic and beta2-agonist on the Activity of Beta-receptors in Healthy Volunteers	nan	UNKNOWN
Mental Ability Challenge Study in Adults With and Without HIV	nan	COMPLETED
Effectiveness of Bryophyllum in Nocturia-Therapy	nan	COMPLETED
Penehyclidine for Prevention of Nausea and Vomiting After Bimaxillary Surgery	nan	COMPLETED
Cholinergic Status and the Metabolic Syndrome	nan	UNKNOWN
Single Photon Emission Computed Tomography to Study Receptors in Parkinson's Disease	nan	COMPLETED
Immunoadsorption Study Mainz in Adults With Post-COVID Syndrome	nan	COMPLETED
Penehyclidine and Postoperative Nausea and Vomiting After Bimaxillary Surgery	nan	COMPLETED
Effects of Prazosin on the Attention-Enhancing Effects of Nicotine	nan	WITHDRAWN
Cholinergic Receptor Imaging in Dystonia	nan	COMPLETED
Brain Imaging in Depression	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CHRM2 binder may also engage these)

Protein	Name	Similarity
P41985	—	1.000	P41985 →
Q9N2A7	—	0.998	Q9N2A7 →
P10980	—	0.996	P10980 →
P30372	—	0.995	P30372 →
P06199	—	0.995	P06199 →
Q9ERZ4	—	0.991	Q9ERZ4 →
P17200	—	0.989	P17200 →
P30544	—	0.980	P30544 →
P32211	—	0.975	P32211 →
CHRM4	Muscarinic acetylcholine receptor M4	0.973	landscape →
P08485	—	0.973	P08485 →
Q56H79	—	0.958	Q56H79 →
Q8BZP8	—	0.957	Q8BZP8 →
S1PR1	Sphingosine 1-phosphate receptor 1	0.957	landscape →
O08530	—	0.956	O08530 →
Q9PUQ8	—	0.955	Q9PUQ8 →
Q9Z0U9	—	0.955	Q9Z0U9 →
Q91559	—	0.955	Q91559 →
P48303	—	0.955	P48303 →
Q333S9	—	0.954	Q333S9 →
O02777	—	0.953	O02777 →
Q9DDK4	—	0.953	Q9DDK4 →
Q71SP5	—	0.953	Q71SP5 →
Q5E9P3	—	0.953	Q5E9P3 →
P20272	—	0.952	P20272 →
Q9PUI7	—	0.952	Q9PUI7 →
P56490	—	0.950	P56490 →
Q98895	—	0.950	Q98895 →
Q5IS73	—	0.950	Q5IS73 →
Q90352	—	0.950	Q90352 →